Health Services Research to Improve Management of mBC Patients Treated with Tucatinib
Pfizer
UM Funding ID
FD03797
Sponsor
Pfizer
Category
International
Description
The intent of this RFP is to support Investigator Sponsored/General Research projects that will implement and assess the impact of therapy management approaches for patients with HER2+ Metastatic Breast Cancer (mBC) receiving tucatinib in combination with trastuzumab and capecitabine.
Individual projects requesting up to $250,000 USD will be considered. Eighteen-month suggested project length (may be shorter or longer).
VPRI Contact
James De Castro
Research Contracts OfficerJames [dot] .DeCastro [at] @umanitoba [dot] .ca
Deadlines
| UM Internal Deadline | Sponsor Deadline | |
|---|---|---|
Application | 21-Jan-2025 4:30 pm CST | 30-Jan-2025 11:59 pm EST |
Important
The information in this directory is provided as a service to the University Community and anyone with legitimate business with the University. Use of this directory to prepare mass mailings is prohibited.